Peroxiredoxin I, platelet-derived growth factor A, and platelet-derived growth factor receptor α are overexpressed in carcinoma ex pleomorphic adenoma: association with malignant transformation

Human Pathology

Volumn 40, Issue 3, 2009, Pages 390-397

  Demasi, Ana Paula Dias ^a   Furuse, Cristiane ^a   Soares, Andresa B ^a   Altemani, Albina ^b   Araújo, Vera C ^a  

^a SÃO LEOPOLDO MANDIC INSTITUTE AND RESEARCH CENTER   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Carcinoma ex pleomorphic adenoma; Peroxiredoxins; Platelet derived growth factor, Platelet derived growth factor receptor; Salivary gland

Indexed keywords

PEROXIREDOXIN 1; PLATELET DERIVED GROWTH FACTOR A; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER STAGING; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MALIGNANT TRANSFORMATION; OXIDATIVE STRESS; PHENOTYPE; PLEOMORPHIC ADENOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION;

ADENOCARCINOMA; ADENOMA, PLEOMORPHIC; ADULT; AGED; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; PEROXIREDOXINS; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; SALIVARY GLAND NEOPLASMS; SALIVARY GLANDS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 59049102796     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2008.06.030     Document Type: Article

References (35)

1. Gnepp D.R., Brandwein-Gensler M.S., El-Naggar A.K., and Nagao T. Carcinoma ex pleomorphic adenoma. In: Barnes L., Eveson J.W., Reichart P., and Sidransky D. (Eds). World Health Organization classification of tumours. Pathology and genetics. Head and neck tumours. 1st ed. (2005), IARC Press, Lyon 242-243
2. Cheuk W., and Chan J.K. Advances in salivary gland pathology. Histopathology 51 (2007) 1-20
3. Ostman A. PDGF Receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev 15 (2004) 275-286
4. Alvarez R.H., Kantarjian H.M., and Cortes J.E. Biology of platelet-derived growth factor and its involvement in disease. Mayo Clin Proc 81 (2006) 1241-1257
5. Doolittle R.F., Hunkapiller M.W., Hood L.E., et al. Simian sarcoma virus onc gene, v-sis, is derived from the gene (or genes) encoding a platelet-derived growth factor. Science 221 (1983) 275-2777
6. Kang S.W. Two axes in platelet-derived growth factor signaling: tyrosine phosphorylation and reactive oxygen species. Cell Mol Life Sci 64 (2007) 533-541
7. Sundaresan M., Yu Z.X., Ferrans V.J., Irani K., and Finkel T. Requirement for generation of H2O2 for platelet-derived growth factor signal transduction. Science 270 (1995) 296-299
8. Bae Y.S., Kang S.W., Seo M.S., et al. Epidermal growth factor (EGF)-induced generation of hydrogen peroxide. Role in EGF receptor-mediated tyrosine phosphorylation. J Biol Chem 272 (1997) 217-221
9. 2, a necessary evil for cell signaling. Science 312 (2006) 1882-1883
10. Chen K.C., Zhou Y., Zhang W., and Lou M.F. Control of PDGF-induced reactive oxygen species (ROS) generation and signal transduction in human lens epithelial cells. Mol Vis 13 (2007) 374-387
11. Fruehauf J.P., and Meyskens Jr. F.L. Reactive oxygen species: a breath of life or death?. Clin Cancer Res 13 (2007) 789-794
12. Kang S.W., Chae H.Z., Seo M.S., Kim K., Baines I.C., and Rhee S.G. Mammalian peroxiredoxin isoforms can reduce hydrogen peroxide generated in response to growth factors and tumor necrosis factor-alpha. J Biol Chem 273 (1998) 6297-6302
13. Meng T.C., Fukada T., and Tonks N.K. Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo. Mol Cell 9 (2002) 387-399
14. Choi M.H., Lee I.K., Kim G.W., et al. Regulation of PDGF signalling and vascular remodelling by peroxiredoxin II. Nature 435 (2005) 347-353
15. Kappert K., Sparwel J., Sandin A., et al. Antioxidants relieve phosphatase inhibition and reduce PDGF signaling in cultured VSMCs and in restenosis. Arterioscler Thromb Vasc Biol 26 (2006) 2644-2651
16. Hofmann B., Hecht H.J., and Flohe L. Peroxiredoxins. Biol Chem 383 (2002) 347-364
17. Wood Z.A., Schröder E., Robin Harris J., and Poole L.B. Structure, mechanism and regulation of peroxiredoxins. Trends Biochem Sci 28 (2003) 32-40
18. Kang S.W., Rhee S.G., Chang T.S., Jeong W., and Choi M.H. 2-Cys peroxiredoxin function in intracellular signal transduction: therapeutic implications. Trends Mol Med 11 (2005) 571-578
19. Prospéri M.T., Ferbus D., Karczinski I., and Goubin G. A human cDNA corresponding to a gene overexpressed during cell proliferation encodes a product sharing homology with amoebic and bacterial proteins. J Biol Chem 268 (1993) 11050-11056
20. Jones A.V., and Cross N.C. Oncogenic derivatives of platelet-derived growth factor receptors. Cell Mol Life Sci 61 (2004) 2912-2923
21. Brandwein M., Huvos A.G., Dardick I., Thomas M.J., and Theise N.D. Noninvasive and minimally invasive carcinoma ex mixed tumor: a clinicopathologic and ploidy study of 12 patients with major salivary tumors of low (or no?) malignant potential. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 81 (1996) 655-664
22. Altemani A., Martins M.T., Freitas L., Soares F., Araújo N.S., and Araújo V.C. Carcinoma ex pleomorphic adenoma (carcinoma ex pleomorphic adenoma): immunoprofile of the cells involved in carcinomatous progression. Histopathology 46 (2005) 635-641
23. Hermanson M., Funa K., Koopmann J., et al. Association of loss of heterozygosity on chromosome 17p with high platelet-derived growth factor alpha receptor expression in human malignant gliomas. Cancer Res 56 (1996) 164-171
24. Chang J.W., Jeon H.B., Lee J.H., et al. Augmented expression of peroxiredoxin I in lung cancer. Biochem Biophys Res Commun 289 (2001) 507-512
25. Yanagawa T., Iwasa S., Ishii T., et al. Peroxiredoxin I expression in oral cancer: a potential new tumor marker. Cancer Lett 156 (2000) 27-35
26. Martins M.T., Altemani A., Freitas L., and Araújo V.C. Maspin expression in carcinoma ex pleomorphic adenoma. J Clin Pathol 58 (2005) 1311-1314
27. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
28. Tchah H., Kim M.J., Kim T.I., et al. Regulation of 1-cys peroxiredoxin expression in the process of stromal wound healing after photorefractive keratectomy. Invest Ophthalmol Vis Sci 46 (2005) 2396-2403
29. Bornfeldt K.E., Raines E.W., Graves L.M., Skinner M.P., Krebs E.G., and Ross R. Platelet-derived growth factor. Distinct signal transduction pathways associated with migration versus proliferation. Ann N Y Acad Sci 766 (1995) 416-430
30. Neumann C.A., Krause D.S., Carman C.V., et al. Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. Nature 424 (2003) 561-565
31. Huang M.E., Rio A.G., Nicolas A., and Kolodner R.D. A genomewide screen in Saccharomyces cerevisiae for genes that suppress the accumulation of mutations. Proc Natl Acad Sci U S A 100 (2003) 11529-11534
32. Chen W.C., McBride W.H., Iwamoto K.S., et al. Induction of radioprotective peroxiredoxin-I by ionizing irradiation. J Neurosci Res 70 (2002) 794-798
33. Wang T., Tamae D., LeBon T., Shively J.E., Yen Y., and Li J.J. The role of peroxiredoxin II in radiation-resistant MCF-7 breast cancer cells. Cancer Res 65 (2005) 10338-10346
34. Chen M.F., Keng P.C., Shau H., et al. Inhibition of lung tumor growth and augmentation of radiosensitivity by decreasing peroxiredoxin I expression. Int J Radiat Oncol Biol Phys 64 (2006) 581-591
35. Sherbenou D.W., and Druker B.J. Applying the discovery of the Philadelphia chromosome. J Clin Invest 117 (2007) 2067-2074